ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
The Global Investment Conference will be held in-person at the Lotte New York Palace Hotel in Midtown
For appointment scheduling, please contact Jennifer K. Zimmons, PhD, MBA at Quantum Media: jen@quantum-corp.com, +1.917.214.3514.
The Global Investment Conference brings together companies, industry professionals, and investors from various sectors, including biotech and life sciences, offering opportunities for networking, one-on-one investor meetings, and company presentations.
For more information and/or to register for the Global Investment Conference, please visit: HCW Events
About ImmunoPrecise Antibodies Ltd.
The IPA Family (as defined below) is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. ImmunoPrecise Antibodies Ltd. has several subsidiaries in
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of applicable
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the Company’s Annual Report on Form 20-F for the year ended April 30, 2024 (which may be viewed on the Company’s SEDAR+ profile at www.sedar.com and EDGAR profile at www.sec.gov/edgar). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826542905/en/
Investor Relations Contact
Kirsten Beduya
Quantum Media Group, LLC
kirsten@quantum-corp.com
Source: ImmunoPrecise Antibodies Ltd.